Nurix Therapeutics (NRIX) Other Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Other Accumulated Expenses data on file, last reported at $1.9 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $1.9 million, down 28.41% year-over-year; the trailing twelve-month figure through Feb 2026 was $1.9 million (down 28.41% YoY), and the FY2025 annual result was $2.1 million, down 7.87% from the prior year.
• Other Accumulated Expenses fell to $1.9 million in Q1 2026 per NRIX's latest filing, from $2.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.7 million in Q1 2025 and troughed at $551000.0 in Q1 2022.
• A 5-year average of $1.4 million and a median of $1.2 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 272.71% in 2022, then slumped 50.03% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.5 million in 2022, then tumbled by 50.03% to $751000.0 in 2023, then soared by 202.93% to $2.3 million in 2024, then retreated by 7.87% to $2.1 million in 2025, then fell by 8.16% to $1.9 million in 2026.
• Business Quant data shows NRIX's Other Accumulated Expenses at $1.9 million in Q1 2026, $2.1 million in Q4 2025, and $1.7 million in Q3 2025.